

CSD/BSE&NSE/2025-26  
July 29, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

**Scrip Code: 543064**

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding issuance of Corporate Guarantee**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Company has provided Corporate Guarantee for an amount upto USD 16.5 million to Citibank N.A. (“Lender”) to secure the credit facility to be availed by NJ Bio Inc., a subsidiary of the Company (“Borrower”) for an amount upto USD 15 million from the Lender.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

We request you to take this information on record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above



## Giving of Corporate Guarantee

Sl	Particulars	Details
a	Name of party for which such guarantees or indemnity or surety was given	NJ Bio Inc., a subsidiary of the Company based in New Jersey, USA
b	Whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The Corporate Guarantee has been provided by the Company for its subsidiary company, NJ Bio Inc. The transaction was done on terms considered to be at arm’s length basis. The promoter/ promoter group/ group companies have no interest in the transaction.
c	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	<p>The Company has provided Corporate Guarantee for an amount upto USD 16.5 million to Citibank N.A. (“Lender”) to secure the credit facility to be availed by NJ Bio Inc., a subsidiary of the Company (“Borrower”) for an amount up to USD 15 million from the Lender.</p> <p>The significant terms and conditions of the Corporate Guarantee, <i>inter alia</i>, are as hereunder:</p> <ol style="list-style-type: none"> <li>In case of failure of the Borrower to pay the amount due to the Lenders under the said credit facility, the Company will be required to pay such amounts upon demand.</li> <li>The liability of the Company under the Corporate Guarantee shall not exceed USD 16.5 million.</li> <li>The Corporate Guarantee shall be valid and shall remain in force up to June 30, 2028. Such termination shall not affect the Guarantor’s liability with respect to any Principal’s Obligations (including contingent obligations) outstanding at the time of such termination.</li> </ol>
d	Impact of such guarantees or indemnity or surety on listed entity	<p>The facility is intended to support NJ Bio Inc.’s requirements in the U.S., specifically in the area of bioconjugation for Antibody-Drug Conjugates (ADCs), thereby strengthening the group’s global CDMO capabilities.</p> <p>The Corporate Guarantee is given for the subsidiary of the Company. In the event of failure on the part of the borrower in repaying the same to the Citibank N.A., the Company guaranteed the due repayment of the same.</p> <p>The Corporate Guarantee provided by the Company to secure the facility to be availed by Borrower (a subsidiary, based in New Jersey, USA) will be a contingent liability of the Company to the extent of facility to be availed by the Borrower. The Company may be required to pay under the Guarantee on failure of the Borrower to do so. The liability of the Company under the Corporate Guarantee shall not exceed USD 16.5 million.</p>

### Cohance Lifesciences Limited

(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad – 500081, Telangana, India.

Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.

Tel: +91 22 6153 9999

